RHYTHM PHARMACEUTICALS, INC. Logo

RHYTHM PHARMACEUTICALS, INC.

Develops precision medicines for rare genetic diseases causing severe obesity and hyperphagia.

RYTM | US

Overview

Corporate Details

ISIN(s):
US76243J1051
LEI:
Country:
United States of America
Address:
222 BERKELEY STREET, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing precision medicines for rare neuroendocrine diseases. The company focuses on treating conditions characterized by hyperphagia (insatiable hunger) and severe obesity that stem from rare genetic deficiencies. Its lead therapeutic, setmelanotide (marketed as IMCIVREE), is a precision medicine designed to address the root cause of these disorders by targeting the melanocortin-4 receptor (MC4R) pathway. Rhythm is advancing a portfolio of treatment options to transform the lives of patients and families affected by these debilitating conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:05
Regulatory News Service
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
English 126.1 KB

Automate Your Workflow. Get a real-time feed of all RHYTHM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RHYTHM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RHYTHM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye GENIL
Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea 225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea 314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America GERN

Talk to a Data Expert

Have a question? We'll get back to you promptly.